ALDX
Aldeyra Therapeutics, Inc.·Healthcare
1.78
11.950%(+0.19)
Market ClosedLast Updated: — ET
52W L: $1.0752W H: $6.17
ALDX NEWS
prnewswire.com
16h ago
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
NEW YORK, April 10, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased Aldeyra securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
globenewswire.com
19h ago
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, April 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. (“Aldeyra” or “the Company”) (NASDAQ: ALDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 3, 2023, and March 16, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before May 29, 2026.
newsfilecorp.com
19h ago
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
New York, New York--(Newsfile Corp. - April 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"), of the important May 29, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Aldeyra securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
globenewswire.com
20h ago
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors
LOS ANGELES, April 10, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Aldeyra Therapeutics, Inc., (“Aldeyra” or the "Company") (NASDAQ: ALDX) investors of a class action on behalf of investors that bought securities between November 3, 2023 and March 16, 2026, inclusive (the “Class Period”). Aldeyra investors have until May 29, 2026 to file a lead plaintiff motion.
globenewswire.com
22h ago
ALDX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aldeyra Therapeutics, Inc. Securities Lawsuit — The Gross Law Firm
NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX).
newsfilecorp.com
1d ago
ALDX EQUITY ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Aldeyra between November 3, 2023 and March 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 9, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX) and reminds investors of the May 29, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
